Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 8/20 | 0.73 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.73 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 2/20 | 0.38 |
| ▸ | PTK6 | Q13882 | 3/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | TTK | P33981 | 4/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | HIPK1 | Q86Z02 | 1/20 | 0.35 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.35 |
| ▸ | HIPK3 | Q9H422 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8241796 | 0.85 | AURKB (1.00) | AURKAAURKBCHEK1FLT3PTK6 | |
| SCHEMBL8246514 | 0.83 | AURKA (0.67) | AURKAAURKBFLT3PTK6TTK | |
| SCHEMBL8240971 | 0.82 | AURKA (0.66) | AURKAAURKBFLT3PTK6DYRK1A | |
| SCHEMBL8240332 | 0.82 | AURKA (1.00) | AURKAAURKBCHEK1FLT3PTK6 | |
| SCHEMBL8241241 | 0.81 | AURKA (0.90) | AURKAAURKBCHEK1FLT3 | |
| SCHEMBL12404449 | 0.79 | AURKB (0.64) | AURKAAURKBCHEK1PTK6DYRK1A | |
| SCHEMBL8241005 | 0.78 | AURKA (0.64) | AURKAAURKBCHEK1FLT3TTK | |
| SCHEMBL8240362 | 0.78 | AURKB (0.88) | AURKAAURKBCHEK1TTK | |
| SCHEMBL8241235 | 0.77 | AURKA (0.81) | AURKAAURKBCHEK1 | |
| SCHEMBL12404542 | 0.76 | AURKA (0.62) | AURKAAURKBCHEK1PTK6TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007056468-A1 | METHODS FOR INHIBITING PROTEIN KINASES | SCHERING CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
| US-20070105864-A1 | Methods for inhibiting protein kinases | SCHERING CORPORATION | 2007-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105864-A1 | Methods for inhibiting protein kinases | PIM1, PIM2, PIM3 | AURKA 5/4885AURKB 24/4885CHEK1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.